Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medicati...

Full description

Bibliographic Details
Main Authors: Sophie Restellini, Waqqas Afif
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
therapeutic drug monitoring
biologic
ustekinumab
vedolizumab
tofacitinib
Online Access:https://www.mdpi.com/2077-0383/10/6/1242
id doaj-3dd4459689334fb28672b0ef241b7f58
record_format Article
spelling doaj-3dd4459689334fb28672b0ef241b7f582021-03-18T00:03:10ZengMDPI AGJournal of Clinical Medicine2077-03832021-03-01101242124210.3390/jcm10061242Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel DiseaseSophie Restellini0Waqqas Afif1Division of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, CanadaDivision of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, CanadaThe goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.https://www.mdpi.com/2077-0383/10/6/1242therapeutic drug monitoringbiologicustekinumabvedolizumabtofacitinib
collection DOAJ
language English
format Article
sources DOAJ
author Sophie Restellini
Waqqas Afif
spellingShingle Sophie Restellini
Waqqas Afif
Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
Journal of Clinical Medicine
therapeutic drug monitoring
biologic
ustekinumab
vedolizumab
tofacitinib
author_facet Sophie Restellini
Waqqas Afif
author_sort Sophie Restellini
title Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
title_short Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
title_full Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
title_fullStr Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
title_full_unstemmed Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
title_sort update on tdm (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2021-03-01
description The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.
topic therapeutic drug monitoring
biologic
ustekinumab
vedolizumab
tofacitinib
url https://www.mdpi.com/2077-0383/10/6/1242
work_keys_str_mv AT sophierestellini updateontdmtherapeuticdrugmonitoringwithustekinumabvedolizumabandtofacitinibininflammatoryboweldisease
AT waqqasafif updateontdmtherapeuticdrugmonitoringwithustekinumabvedolizumabandtofacitinibininflammatoryboweldisease
_version_ 1724217935558344704

Similar Items